Blog
.jpeg)
FDA Modernization Act & What It Means for VeriSIM Life
The FDA Modernization Act strikes out the language referencing animal testing and introduces, in its place, “non-clinical tests” such as those made possible by AI and data modeling. This change has seen a level of bipartisan support rarely witnessed in legislation today, and it is a critical milestone in the history of R&D in that it supports use of simulation and predictive technologies to increase efficiency and candidate success.VeriSIM Life has been ahead of the curve in recognizing these advantages for five years and counting, pioneering the way towards this inevitable industry change by using technology to help clients increase the efficacy of preclinical testing while taking measures towards “de-risking” the process.
FDA Modernization Act & What It Means for VeriSIM Life
The FDA Modernization Act strikes out the language referencing animal testing and introduces, in its place, “non-clinical tests” such as those made possible by AI and data modeling. This change has seen a level of bipartisan support rarely witnessed in legislation today, and it is a critical milestone in the history of R&D in that it supports use of simulation and predictive technologies to increase efficiency and candidate success.VeriSIM Life has been ahead of the curve in recognizing these advantages for five years and counting, pioneering the way towards this inevitable industry change by using technology to help clients increase the efficacy of preclinical testing while taking measures towards “de-risking” the process.
Biosimulation in Depth: A Detailed Guide
Biosimulation, which uses computer simulations of biological processes to predict the behavior of biological systems, is on a significant growth trajectory – thanks in part to the FDA’s strong recommendation for adopting biosimulation, an overall increase in predictive biosimulation in the research and development (R&D) process, and the recent use of biosimulation platforms for the development of COVID-19 vaccines. Now, as pharmaceutical and biotech companies continue to invest in artificial intelligence (AI)-enabled tools and technologies, we should expect to see even more widespread adoption of biosimulation across drug discovery and development.
Biosimulation in Depth: A Detailed Guide
Biosimulation, which uses computer simulations of biological processes to predict the behavior of biological systems, is on a significant growth trajectory – thanks in part to the FDA’s strong recommendation for adopting biosimulation, an overall increase in predictive biosimulation in the research and development (R&D) process, and the recent use of biosimulation platforms for the development of COVID-19 vaccines. Now, as pharmaceutical and biotech companies continue to invest in artificial intelligence (AI)-enabled tools and technologies, we should expect to see even more widespread adoption of biosimulation across drug discovery and development.
Mechanistic Models in Theory and in Practice
Mechanistic models serve as a useful candidate for modeling the detailed inner workings of a system in a true-to-life manner, going above and beyond simulating basic input and output. They can be used as a tool to improve preclinical translatability, reduce time and cost investments, and solve real-world problems safely.
Mechanistic Models in Theory and in Practice
Mechanistic models serve as a useful candidate for modeling the detailed inner workings of a system in a true-to-life manner, going above and beyond simulating basic input and output. They can be used as a tool to improve preclinical translatability, reduce time and cost investments, and solve real-world problems safely.
When It Comes to AI in Drug Development, Should We Believe the Hype?
AI technologies like deep learning, machine learning and natural language processing have the potential to address many of the challenges that traditionally plague drug R&D – accelerating molecule design and testing, streamlining essential processes, improving chances of clinical success, and reducing costs throughout the development pipeline.
When It Comes to AI in Drug Development, Should We Believe the Hype?
AI technologies like deep learning, machine learning and natural language processing have the potential to address many of the challenges that traditionally plague drug R&D – accelerating molecule design and testing, streamlining essential processes, improving chances of clinical success, and reducing costs throughout the development pipeline.
.png)
Introducing AtlasGEN™ Novel Drug Designer
AtlasGEN Novel Drug Designer efficiently identifies new molecules based on favorable chemical properties and simultaneously evaluates them for clinical safety and effectiveness based on biology using VeriSIM Life’s groundbreaking Translational Index™ technology.
Iterative ranking of target engaging hits by their Translational Index values reduces the time and cost associated with other computational hit discovery approaches, while compressing the hit-to-lead refinement and optimization process by pre-validating hits for translatability. This unique integration dramatically reduces the number of compounds to evaluate in subsequent experimental research.
The ability to generate target engaging compound hits depends largely on the size of the molecular search library. The AtlasGEN search space is supported by more than 1 trillion compounds. Generative AI and deep learning techniques deliver unprecedented discovery capability.
AtlasGEN accurately predicts protein-lygand binding affinity by combining geometric conformer analysis with machine learning based on experimental data 72% more efficiently than molecular docking-based approaches.
